The battle within the atypical antipsychotics market has grown fierce in recent years, as leading manufacturers vie for a larger share of the prescriptions written for psychotic disorders. Faced with this harshly competitive environment, drug manufacturers are employing creative strategies to maintain their market shares. A new Decision Resources study, Overview of Antipsychotics, evaluates these efforts and the therapeutic and commercial potential of the resulting therapies over a 2000-2010 forecast period.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Pfizer's Ziprasidone Challenges Lilly's Olanzapine
We believe that olanzapine (Eli Lilly's Zyprexa) and risperidone (Janssen's Risperdal) will hold their current market positions throughout the decade, but both will be challenged by growing use of other atypical agents, most notably Pfizer's ziprasidone (Geodon/Zeldox), which lacks the weight-gain side-effects that are linked to the market leaders. Lilly appears to have somewhat of a competitive advantage over Pfizer because olanzapine was launched earlier than ziprasidone; olanzapine has broader labeling (it is also approved for the treatment of acute manic exacerbations of BPD); and olanzapine will soon be available in both short- and long-acting injectable formulations.
New Avenues for Treatment and Commercial Success
The availability of atypical agents in short-acting intramuscular (IM) formulations will expand the use of these drugs in acute settings. The commercial benefit of this strategy lies in the likelihood that physicians will opt to continue patients on an oral or depot version of the same drug that is administered in the acute setting. Thus, the availability of olanzapine and ziprasidone in short-acting IM formulations will give these drugs a competitive advantage over other atypical agents.
Other notable developments include the emergence of depot forms of atypical agents. Such formulations remain effective for weeks following administration and have the potential to improve compliance with antipsychotic medications (a major unmet need in psychotic disorders).
Overview of Antipsychotics offers invaluable market intelligence for pharmaceutical companies competing in this market. This study is part of Cognos, one of six Pharmacor services from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,